Johnson & Johnson Innovative Medicine
Pharmaceutical Companies of Johnson and Johnson
DARZALEX (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
88% of transplant-eligible patients achieved a complete response or better, and 47% of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the phase 3 PERSEUS study 7.5 years median overall survival achieved with daratumumab-based regimen in phase 3 MAIA final survival analysis is the longest reported in patients ineligible...
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
Submission is supported by data from the phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting New formulation showed non-inferiority to intravenous administration in fourth positive phase 3 amivantamab study Longer overall survival, progression-free survival and duration of response shown with subcutaneous amivantamab; featured in Best of ASCO 2024....
RYBREVANT▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark phase 3 MARIPOSA data featured in an oral presentation at ASCO 2024. 31 May 2024 -- Beerse, Belgium -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new data from the...
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations 5 May 2024 -- Beerse, Belgium -- Janssen-Cilag International, a Johnson & Johnson company, announced today updated results from an open-label, multicentre, multi-cohort phase 1 study of the safety and efficacy of TAR-210, an...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
New data from phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ – a disease area with limited treatment options for patients. 3 May 2024...
Phase 2 data for ERLEADA ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100% biochemical free recurrence rate more than two years post-surgery
Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localised prostate cancer (HRLPC) experience disease recurrence within two years of surgery 3 May 2024 -- Beerse, Belgium -- Janssen-Cilag International, a Johnson & Johnson company, announced today results from the open-label, single-arm phase 2 Apa-RP study evaluating adjuvant treatment...
Janssen to adopt Johnson & Johnson brand as the Company celebrates 100 years of operating in the UK
Johnson & Johnson marks new era in the UK with updated visual identity 1 May 2024 -- High Wycombe, UK -- Johnson & Johnson today announced it is updating its brand and uniting both its two business segments under the Johnson & Johnson brand name in the UK. The announcement marks the next era for...
Johnson & Johnson receives positive CHMP opinion for RYBREVANT▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC The recommendation is supported by data from the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly improved progression-free survival in adult patients, versus chemotherapy alone. 26...
CARVYKTI▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the EC for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the phase 3 CARTITUDE-4 study, in which treatment with cilta-cel in 1-3 prior lines of therapy reduced the risk of disease progression or death by...
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
Submission supported by data from phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk of progression or death, compared to standard of care regimen 5 March 2024 – Beerse, Belgium – Janssen-Cilag International NV, a Johnson & Johnson company, today announced the submission of a Type II variation application...
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
0800 731 5550
